A factor VIII-mimetic antibody for haemophilia A
Emicizumab
A regular preventive injection for haemophilia A that mimics a missing clotting factor to reduce bleeds.
What is Emicizumab?
Emicizumab is a biologic injection used to help prevent bleeds in people with haemophilia A, a condition where the blood is missing clotting factor VIII. It is an antibody that does the job of the missing factor, bringing together the other clotting proteins so blood can clot. It is given as a regular injection under the skin to prevent bleeds; it is not a treatment for an active bleed. A key safety point is that dangerous blood clots can occur if certain rescue clotting treatments (aPCC/FEIBA) are used alongside it, and it also interferes with some standard clotting blood tests.
Education and reference only. This is a plain-language guide to Emicizumab — it deliberately contains no doses. Doses depend on the person, the brand and the reason for treatment, and belong with your prescriber. Always check the BNF, the product labelling (SmPC) and follow medical advice.
What it is
Emicizumab is a biologic medicine, a laboratory-made antibody, used as regular prevention (prophylaxis) to reduce or prevent bleeding in people with haemophilia A, a usually inherited condition in which the blood lacks enough clotting factor VIII. It can be used by people who have developed inhibitors (antibodies against factor VIII) as well as those who have not. It is given as an injection under the skin, which can be done at home after training, at regular intervals.
How it works
In haemophilia A, the missing or low factor VIII means the clotting process cannot proceed properly, so bleeding is hard to stop. Emicizumab works by bridging two other clotting proteins (factor IXa and factor X), taking over the bridging role that factor VIII would normally play. This restores enough of the clotting process to prevent many bleeds. Because it works in a different way from factor VIII, it can help even people whose bodies have made inhibitors against factor VIII. It is preventive and works steadily, rather than stopping a bleed once it has started.
Company & origin
Originated / developed by: Roche.
A biologic injection used in the UK to help prevent bleeds in people with haemophilia A, by mimicking a missing clotting factor.
Practical use
How to take Emicizumab
General, dose-free guidance — always follow your prescriber's and the leaflet's specific instructions.
- It is given as an injection under the skin at regular intervals, which you or a carer can usually do at home after training.
- Remember it prevents bleeds but does not treat an active bleed; follow the breakthrough-bleed plan agreed with your haemophilia centre.
- Do not use bypassing agents such as aPCC (FEIBA) for a bleed without specialist guidance, as combining them can cause dangerous clots.
- Tell any doctor, nurse or laboratory that you are on emicizumab, as it affects some clotting blood tests.
- Carry information that you take emicizumab so the right advice is given in an emergency.
Weighing it up
Advantages & disadvantages of Emicizumab
Advantages
- Substantially reduces bleeds in haemophilia A, including in people who have developed factor VIII inhibitors.
- Given as an injection under the skin, often at home, rather than into a vein.
- Can be given at spaced-out intervals, which is more convenient than frequent factor injections for many people.
Disadvantages
- Prevents bleeds but does not treat an active bleed, so a separate breakthrough-bleed plan is still needed.
- Carries a risk of dangerous blood clots if certain rescue treatments (aPCC/FEIBA) are used alongside it.
- Interferes with some standard clotting blood tests, which can give misleading results.
Practical use
Good to know
Two safety points are especially important with emicizumab. First, it is a preventive medicine that lowers the chance of bleeds, but it does not stop an active bleed, so you still need a plan for treating breakthrough bleeds, agreed with your haemophilia centre. Crucially, using certain rescue treatments called bypassing agents (especially activated prothrombin complex concentrate, aPCC or FEIBA) while on emicizumab can cause dangerous blood clots and a serious condition affecting small blood vessels (thrombotic microangiopathy), so these must only be used under strict specialist guidance. Second, emicizumab interferes with some standard clotting blood tests (those based on the activated clotting time), which can give misleading results, so laboratories and other doctors must know you are on it. Always carry information that you take emicizumab and tell any healthcare professional, especially in an emergency.
Who should not take it / use with caution
- People who have had a serious allergic reaction to emicizumab should not have it again.
- It is used with great caution alongside bypassing agents such as aPCC (FEIBA), which can cause dangerous clots.
- It should only be used under specialist haemophilia care, with a clear plan for treating breakthrough bleeds.
Monitoring
- Reviewing how well bleeds are being prevented and adjusting the overall plan as needed.
- Using only clotting tests that are not affected by emicizumab, and informing the laboratory.
- Watching for signs of clots or thrombotic microangiopathy, especially if rescue treatments are used.
Side effects
- Injection-site reactions, headache and joint aches are among the more common effects.
- Rarely, serious blood clots or thrombotic microangiopathy, particularly if used with certain rescue treatments.
- Cold-like symptoms or a raised temperature in some people.
Key interactions
- Using activated prothrombin complex concentrate (aPCC, FEIBA) alongside it can cause dangerous clotting and must be avoided or strictly controlled.
- It interferes with some clotting blood tests, so laboratories must know you are on it to interpret results correctly.
- Tell your haemophilia team about all medicines, including any other clotting treatments, before any procedure.
Available as: Injection under the skin (prefilled vials), given at regular intervals.
Answers
Emicizumab: frequently asked questions
Can emicizumab stop a bleed that has already started?
No. It is a preventive treatment that reduces how often bleeds happen; an active bleed still needs the breakthrough-bleed plan agreed with your haemophilia centre.
Why is mixing it with FEIBA dangerous?
Using bypassing agents such as aPCC (FEIBA) alongside emicizumab can cause dangerous blood clots and a serious blood-vessel condition, so they must only be used under strict specialist guidance.
Will it affect my blood tests?
Yes. Emicizumab interferes with some standard clotting tests, so always tell the laboratory and your doctors that you take it, so the right tests and interpretation are used.
Can it be used if I have inhibitors?
Yes. Because it works differently from factor VIII, it can help prevent bleeds in people who have developed inhibitors as well as those who have not.
Can I give the injection at home?
Yes, after training, you or a carer can usually give the injection under the skin at home at the intervals your team advises.
Authoritative sources
- BNF
- NICE CKS
Building a medicines information resource?
We create evidence-led, dose-free drug and formulary references for teams.